Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Y-Mabs Therapeutics Inc (YMAB)

Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Y-Mabs Therapeutics Inc 202 Carnegie Center Suite 301 PRINCETON NJ 08540 USA

www.ymabs.com Employees: 107 P: 646-885-8505

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA.

Key Statistics

Overview:

Market Capitalization, $K 391,221
Enterprise Value, $K 323,991
Shares Outstanding, K 45,438
Float, K 36,487
% Float 80.30%
Short Interest, K 1,068
Days to Cover 1.67
Short Volume Ratio 0.50
% of Insider Shareholders 19.70%
% of Institutional Shareholders 70.85%

Financials:

Annual Sales, $ 87,690 K
Annual Net Income, $ -29,670 K
Last Quarter Sales, $ 19,530 K
Last Quarter Net Income, $ -3,240 K
EBIT, $ -26,650 K
EBITDA, $ -26,110 K

Growth:

1-Year Return -37.34%
3-Year Return -38.32%
5-Year Return -77.04%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 70.87%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.07 on 08/08/25
Next Earnings Date 11/14/25
Earnings Per Share ttm -0.50
EPS Growth vs. Prev Qtr 41.67%
EPS Growth vs. Prev Year 66.67%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

YMAB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -24.60%
Return-on-Assets % -18.89%
Profit Margin % -33.84%
Debt/Equity 0.00
Price/Sales 4.45
Price/Cash Flow N/A
Price/Book 4.46
Book Value/Share 1.93
Interest Coverage -0.46
60-Month Beta 0.53
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar